265 related articles for article (PubMed ID: 21734048)
1. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.
Paglino JC; van den Pol AN
J Virol; 2011 Sep; 85(18):9346-58. PubMed ID: 21734048
[TBL] [Abstract][Full Text] [Related]
2. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
3. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Heiber JF; Barber GN
J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
[TBL] [Abstract][Full Text] [Related]
4. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
6. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
7. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
8. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.
van den Pol AN; Davis JN
J Virol; 2013 Jan; 87(2):1019-34. PubMed ID: 23135719
[TBL] [Abstract][Full Text] [Related]
9. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
[TBL] [Abstract][Full Text] [Related]
11. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
12. SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Muscolini M; Castiello L; Palermo E; Zevini A; Ferrari M; Olagnier D; Hiscott J
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092575
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
[TBL] [Abstract][Full Text] [Related]
14. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
15. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
Felt SA; Droby GN; Grdzelishvili VZ
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
[TBL] [Abstract][Full Text] [Related]
17. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
18. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Moon J; Kaowinn S; Cho IR; Min DS; Myung H; Oh S; Kaewpiboon C; Kraemer OH; Chung YH
Biochem Biophys Res Commun; 2016 Jun; 474(3):428-434. PubMed ID: 27150631
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]